

Poster numbers poster presentations

Nr.	Titel of poster abstract	Presenting author
1	Lamotrigine Use in Lactating Women: Passage into Breast Milk and Infant Exposure	Daphne den Besten-Bertholee
2	Identifying high-risk medication during pregnancy for adverse pregnancy outcomes in Electronic Patient Files (EPF) using disproportional analysis	Dr. Peter Ter Horst
3	Medication screening in pregnant women for cord blood donation in extremely preterm neonates	Robert Flint
4	Spontaneous adverse drug reaction reporting of congenital malformations, a Danish national register study	MD, Associate Professor Christina Gade
5	Pediatric medication from off-label to on-intelligent-evidence	Anette Kirstine Stark
6	Angiotensin II/angiotensin I ratio as pharmacodynamic parameter in healthy adults and children with heart failure treated with enalapril: insights from an adult population pharmacokinetic-pharmacodynamic model and the LENA studies	Melina Steichert
7	A pharmacovigilance study on the association between proton-pump inhibitors and inappropriate neonatal use based on the FAERS database	Assoc. Prof. Nadir Yalcin
8	AMI FABRY – A Triple Relief for Pain, Gut, and Mood in Fabry Disease using Amitriptylin	Anna-Maria Wiesinger
9	Drug interactions in critically ill neonates undergoing therapeutic hypothermia: a single centre study.	PharmDr. Kateřina Kaňková
10	Leveraging existing evidence on off-label prescribed drugs to support effective and safe pharmacotherapy: Pediatrics as an example.	Dr. Tjitske van der Zanden
11	A review on the role of extrapolation as basis for paediatric marketing authorisation applications of medicines in the EU.	Loes Maton
12	Reaching sufficient evidence in small populations: a scoping review of methods and regulatory guidance	Laurens Sluiterman
13	On-Label Paediatric Drug Product Information in Switzerland – the Neglected Child	Lukas Higi
14	Evaluation of nine population pharmacokinetic models for model-based vancomycin concentration monitoring in a local population of neonates	Verena Gotta
15	MEDeHelp –development of an emergency mobile application for Europe	Karin Kaeser
16	Paracetamol concentrations and time-course of ductus arteriosus diameter in extreme preterm neonates: a population pharmacokinetic-pharmacodynamic analysis	Faheemah Padavia
17	The REPAIR-NEO study protocol to test a workflow on drug development in neonates undergoing therapeutic hypothermia.	Prof. dr. Karel Allegaert
18	Quantifying milk and maternal postpartum changes to improve drug safety in breastfeeding	PhD Neel Deferm
19	Developing evidence-based dosing recommendations for intravenous ciprofloxacin in critically ill children: a population pharmacokinetic study using total and unbound concentrations	PhD Pieter-Jan De Sutter
20	In vivo cytochrome P450 1A2 activity in adolescents with and without obesity	MD, Associate Professor Christina Gade
21	Assessing the predictive performance of a population pharmacokinetic model for paracetamol and its metabolites in an external dataset of neonates, infants, and children receiving paracetamol as analgesic after cardiac surgery.	Vita Melton
22	Population pharmacokinetics of morphine in children under 3 years after cardiothoracic surgery: External validation and extrapolation of published models	Maria Xiberras
23	Use of virtual populations to investigate 'weekend-off' efavirenz dosing in adults and adolescents with different CYP2B6 526 G>T genotypes	Dr. Lisa Almond
24	optimizing high-dose methotrexate dosing for the treatment of infant acute lymphoblastic leukemia	MSc Tirsa de Kluis
25	Establishing evidence-based, model-informed dose recommendations for amoxicillin in pregnancy	Dagmar Hiensch
26	Optimizing paediatric opioid conversion and methadone tapering: physiologically-based pharmacokinetic modelling in critically ill children	MSc Marika de Hoop
27	Physiologically Based Pharmacokinetic Modeling of Ivacaftor/Tezacaftor/Elxacaftor in Children with Cystic Fibrosis: Evaluating Hepatic and Intestinal CYP3A4 Ontogeny	Femke Elzinga
28	Evidence-based dose recommendations for preterm and term neonates: the neodose project	Lianne van Bussel
29	Optimization of microdialysis experiments to study antibiotic disposition in children: lessons learnt	Ir. Isis Van herterryck
30	Weight-based dosing of monoclonal antibodies in paediatrics: a systematic study of population pharmacokinetics studies to evaluate its impact on exposure of infliximab across the paediatric age range	Tine Mirchi
31	Plasma protein binding: can we use piglets to study unbound drug disposition in children?	Ir. Isis Van herterryck
32	Osmolality of oral liquid medications intended for neonates and infants: a laboratory-based study	Dotan Shaniv
33	Hyperosmolar preparations and necrotizing enterocolitis: can a single overdose tip the balance? a case report	Dotan Shaniv
34	Ontogeny of hepatic and intestinal CYP3A activity across the pediatric age range quantified using population Physiologically-Based Pharmacokinetic modelling	Aymara Sancho Araiz
35	Drug utilisation at a German neonatal intensive care unit – Are evidence-based (off-label) dosing recommendations available?	Dr. Sonja Eberl
36	Coproporphyrin I as biomarker in a pediatric population: Age-related differences and genetic influences	Leila Potzel
37	Extravasation of Vesicant and Irritant Drugs in Pediatric Patients-A Literature Review	Dr. med. Christiane Garnemark
38	The reality of prescribing selected medications in the pediatric population: a single centre experience.	Pavla Pokorna
39	Personalized Immunomodulatory Drug Repurposing in Patients with Mucopolysaccharidosis	Anna-Maria Wiesinger
40	"Meet the Pain" is an educational multidisciplinary project to improve the pain assessment skills of neonatal intensive care unit nurses	MD Hana Jancova
41	To re-dose or not? A decision-making flowchart after vomiting in the paediatric population	Sahar Alozaï
42	Causality, Severity and Avoidability of Adverse Drug Reactions in Children over an 11-year period	Dr. Duaa Gaafar
43	Trends in paediatric hypnotic prescriptions in France, 2016-2023	Zaba Valtuille
44	Patterns of paediatric methylphenidate users: a national time series analysis from 2016 to 2023	Zaba Valtuille
45	Model-based blood pressure prediction for personalized medicine for people at any age	Sabina Schlottau
46	Maternal drug use and infant exposure during breastfeeding	Ditte Resendal
47	Effect of SARS-CoV-2 on psychotropic drug use in children: a population-based longitudinal study	Mag.pharm. Dr. Hans-Jürgen Gober
48	Predictive performance, and model refinement, of physiologically based pharmacokinetic (PBPK) models for CYP3A inhibitors clarithromycin and fluconazole in a virtual paediatric population	Roz Southall
49	Integrated, multimodal collaboration to support paediatric pharmacology and drug development: the conect4children (c4c) project and c4c stichting	Fenna Mahler
50	Comparison of maternal and fetal exposure to escitalopram, sertraline, and paroxetine during pregnancy combining human ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling	Gabrielle LUI
51	Comparative analysis of breast milk and infant formulas: microbiome and health implications	PhD candidate David Rojas-Velazquez
52	Sedative antipsychotic use by children and adolescents in the Netherlands: Dosages, duration and prescribers	Ir. Ravish Gangapersad
53	Impact of Discontinuing Open-Label Doxapram use in Neonates on Informed Consent Rates in the DOXA-Trial	Kelly Storm
54	The CANDi project's first step: prioritization of off-label drug-indications warranting further assessment.	Dr. Violette Gijsen
55	Trends in hospitalizations for accidental poisoning in children in France, 2016-2023	Zaba Valtuille